Ensign Peak Advisors, Inc Chemo Centryx, Inc. Transaction History

Ensign Peak Advisors, Inc

$56.1 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 12, 2022	BUY	$15.36 - $27.51 $365,306 - $654,270	23,783 Added 32.6%	96,746 $2.4 Million
Q4 2021 Feb 11, 2022	BUY	$18.38 - $40.5 $1.34 Million - $2.96 Million	72,963 New	72,963 $2.66 Million
Q2 2021 Aug 13, 2021	SELL	$9.59 - $50.88 $356,978 - $1.89 Million	-37,224 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$46.35 - $61.69 $1.04 Million - $1.39 Million	22,540 Added 153.5%	37,224 $2.04 Million
Q2 2020 Aug 12, 2020	BUY	$38.58 - $65.07 $117,977 - $198,984	3,058 Added 26.3%	14,684 $845,000
Q1 2020 May 11, 2020	BUY	$32.73 - $50.78 $259,516 - $402,634	7,929 Added 214.47%	11,626 $467,000
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $25,176 - $146,216	3,697 New	3,697 $146,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.